These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

976 related items for PubMed ID: 16932648

  • 1. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus.
    Eisenberg R, Albert D.
    Nat Clin Pract Rheumatol; 2006 Jan; 2(1):20-7. PubMed ID: 16932648
    [Abstract] [Full Text] [Related]

  • 2. Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus.
    Goldblatt F, Isenberg DA.
    Handb Exp Pharmacol; 2008 Jan; (181):163-81. PubMed ID: 18071946
    [Abstract] [Full Text] [Related]

  • 3. Crossroads of B cell activation in autoimmunity: rationale of targeting B cells.
    Dörner T.
    J Rheumatol Suppl; 2006 May; 77():3-11. PubMed ID: 16652439
    [Abstract] [Full Text] [Related]

  • 4. B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application.
    Mease PJ.
    J Rheumatol; 2008 Jul; 35(7):1245-55. PubMed ID: 18609733
    [Abstract] [Full Text] [Related]

  • 5. New treatments for SLE: cell-depleting and anti-cytokine therapies.
    Anolik JH, Aringer M.
    Best Pract Res Clin Rheumatol; 2005 Oct; 19(5):859-78. PubMed ID: 16150407
    [Abstract] [Full Text] [Related]

  • 6. B cell-directed therapies for autoimmune disease and correlates of disease response and relapse.
    Levesque MC, St Clair EW.
    J Allergy Clin Immunol; 2008 Jan; 121(1):13-21; quiz 22-3. PubMed ID: 18206502
    [Abstract] [Full Text] [Related]

  • 7. Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers.
    Dörner T, Kinnman N, Tak PP.
    Pharmacol Ther; 2010 Mar; 125(3):464-75. PubMed ID: 20097226
    [Abstract] [Full Text] [Related]

  • 8. B-cell-targeted therapy for systemic lupus erythematosus.
    Sabahi R, Anolik JH.
    Drugs; 2006 Mar; 66(15):1933-48. PubMed ID: 17100405
    [Abstract] [Full Text] [Related]

  • 9. What is the role of rituximab in the treatment of rheumatoid arthritis?
    Atzeni F, Doria A, Turiel M, Sarzi-Puttini P.
    Autoimmun Rev; 2007 Sep; 6(8):553-8. PubMed ID: 17854748
    [Abstract] [Full Text] [Related]

  • 10. B cell targeted therapies in autoimmune diseases.
    Isenberg DA.
    J Rheumatol Suppl; 2006 May; 77():24-8. PubMed ID: 16652442
    [Abstract] [Full Text] [Related]

  • 11. [B cells as key contributors in determining the level of immune responses -B-cell-targeted therapy in patients with autoimmune diseases].
    Kondo S, Akashi T, Katsuta H, Iwakiri R, Anzai K, Nagafuchi S, Niho Y, Harada M.
    Fukuoka Igaku Zasshi; 2005 Apr; 96(4):86-92. PubMed ID: 15991605
    [Abstract] [Full Text] [Related]

  • 12. The therapeutic potential of anti-CD20 "what do B-cells do?".
    Eisenberg R, Looney RJ.
    Clin Immunol; 2005 Dec; 117(3):207-13. PubMed ID: 16169773
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Rituximab: a promising therapy in systemic lupus erythematosus.
    Thatayatikom A, White AJ.
    Autoimmun Rev; 2006 Jan; 5(1):18-24. PubMed ID: 16338207
    [Abstract] [Full Text] [Related]

  • 20. Monoclonal antibodies and fusion proteins and their complications: targeting B cells in autoimmune diseases.
    Lee S, Ballow M.
    J Allergy Clin Immunol; 2010 Apr; 125(4):814-20. PubMed ID: 20371395
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.